मूलभूत आँकड़े
| LEI | 549300BWJLIT2S349463 |
| CIK | 1610853 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Helius Medical Technologies, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 14, 2025 |
Placement Agency Agreement dated June 4, 2025 by and between the Company and Maxim Group LLC Exhibit 10.4 PLACEMENT AGENCY AGREEMENT June 4, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Helius Medical Technologies, Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $9,053,322 of units, each unit consisting of (1 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| July 10, 2025 |
As filed with the Securities and Exchange Commission on July 10, 2025 Registration No. |
|
| July 10, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| July 10, 2025 |
Second Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan Exhibit 4.11 AMENDMENT 2 TO HELIUS MEDICAL TECHNOLOGIES, INC. 2022 Equity Incentive Plan RECITALS A. Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the “Plan”). B. The Plan is amended by this Amendment 2 (this “Second Amendment”) in the following respects, effecti |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (IRS Employer of incor |
|
| July 7, 2025 |
Helius Medical Technologies, Inc. Up to $25,000,000 Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270433 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated June 23, 2023 and March 26, 2025 and Prospectus dated May 25, 2023) Helius Medical Technologies, Inc. Up to $25,000,000 Class A Common Stock This prospectus supplement amends and supplements the prospectus supplements, dated June 23, 2023 and March 26, 2025 (the |
|
| June 27, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. Helius Medical Technologies, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Helius Medical Technologies, Inc. and the da |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 23, 2025 |
Helius Medical Technologies, Inc. Unaudited Condensed Interim Consolidated Balance Sheet Exhibit 99.1 Helius Medical Technologies, Inc. Unaudited Condensed Interim Consolidated Balance Sheet The unaudited balance sheet has been filed in order to show compliance with the Nasdaq requirement that the Company maintain a minimum stockholders' equity of $2.5 million for continued listing. The unaudited balance sheet presents the Company’s balance sheet as June 17, 2025 and gives effect to t |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 6, 2025 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-287572 PROSPECTUS HELIUS MEDICAL TECHNOLOGIES, INC. 2,627,050 Shares of Common Stock or Pre-Funded Warrants to Purchase up to 141,550 Shares of Common Stock, Common Warrants to Purchase up to 2,768,600 Shares of Common Stock and Placement Agent Warrants to Purchase up to 138,430 Shares of Common Stock Up to 45,122,565 Shares |
|
| June 4, 2025 |
Exhibit 99.1 Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria -Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirement- NEWTOWN, Pa., June 4, 2025 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeu |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (IRS Employer of incor |
|
| June 3, 2025 |
June 3, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Ladies and Gentlemen: Maxim Group LLC (“Maxim”), as placement agent, hereby respectfully requests the withdrawal of its acceleration request letter filed as correspondenc |
|
| June 2, 2025 |
June 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Nick O’Leary Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Acceleration Request Requested Date: June 4, 2025 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Helius Medical Technologies, Inc. (t |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38445 (Commission file number) 642 Newtown Yardley Road, Suite 100 Newtown, PA (Address of principal executive offices) 18940 (Zip Code) Dane |
|
| May 30, 2025 |
Exhibit 1.01 Helius Medical Technologies, Inc. Conflict Minerals Report For Calendar Year 2024 Helius Medical Technologies, Inc. (“Helius,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2024, pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange C |
|
| May 28, 2025 |
May 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Jessica Ansart Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Acceleration Request Requested Date: May 29, 2025 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Sec |
|
| May 28, 2025 |
May 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amend |
|
| May 23, 2025 |
Form of Placement Agency Agreement Exhibit 10.24 PLACEMENT AGENCY AGREEMENT May [·], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Helius Medical Technologies, Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $ of units, each unit consisting of (1) eithe |
|
| May 23, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| May 23, 2025 |
Form of Securities Purchase Agreement Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May , 2025, between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| May 23, 2025 |
Form of Placement Agent Warrant to Purchase Shares of Common Stock Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| May 23, 2025 |
Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 23, 2025. |
|
| May 23, 2025 |
Form of Common Warrant to Purchase Shares of Common Stock Exhibit 4.2 COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “In |
|
| May 2, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| April 30, 2025 |
Helius Medical Technologies Announces Reverse Stock Split Exhibit 99.1 Helius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 |
|
| April 30, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. Helius Medical Technologies, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Helius Medical Technologies, Inc. and the da |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| April 25, 2025 |
Exhibit 4.1 [FORM OF SENIOR NOTE] THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT |
|
| April 25, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to t |
|
| April 25, 2025 |
Form of Placement Agency Agreement Exhibit 10.2 April 24, 2025 Dane C. Andreeff President and Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Dear Mr. Andreeff: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Helius Medical Technologies, Inc., a Delaware corporation, (the “Company”), that |
|
| April 25, 2025 |
Exhibit 10.3 FORM OF LOCK-UP AGREEMENT , 2025 Re: Securities Purchase Agreement, dated as of , 2025 (the “Purchase Agreement”), between Helius Medical Technologies, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have |
|
| April 22, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 22, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| April 15, 2025 |
CONFIDENTIAL SUBMISSION VIA EDGAR CONFIDENTIAL SUBMISSION VIA EDGAR April 15, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Draft Registration Statement on Form S-1 Confidentially Submitted on April 15, 2025 CIK No. 0001610853 Ladies and Gentlemen: On behalf of Helius Medical Technologies, Inc. (the “Company”), we have c |
|
| April 15, 2025 |
TABLE OF CONTENTS As confidentially submitted with the Securities and Exchange Commission on April 15, 2025. |
|
| April 4, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| March 26, 2025 |
Helius Medical Technologies, Inc. Up to $1,444,764 Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270433 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated June 23, 2023 and Prospectus Dated May 25, 2023) Helius Medical Technologies, Inc. Up to $1,444,764 Class A Common Stock This prospectus supplement amends and supplements the information in the sales agreement prospectus, dated May 25, 2023 (the “Prospectus”), file |
|
| March 26, 2025 |
Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, PA 1894 Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, PA 1894 March 26, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Margaret Sawicki Re: Helius Medical Technologies, Inc. Registration Statement on Form S-3 Filed January 31, 2025 File No. 333-284633 Acceleration Request Lad |
|
| March 25, 2025 |
Subsidiaries of Helius Medical Technologies, Inc. Exhibit 21.1 SUBSIDIARIES OF HELIUS MEDICAL TECHNOLOGIES, INC ENTITY NAME JURISDICTION Helius Medical, Inc. Delaware Revelation Neuro, Inc. Texas Helius Medical Technologies (Canada), Inc. Canada |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 HELIUS ME |
|
| March 25, 2025 |
Exhibit 19.1 Helius Medical Technologies, Inc. Insider Trading Compliance Policy Effective November 21, 2023 This Insider Trading Compliance Policy (this “Policy”) consists of four sections: Section I provides an overview; Section II sets forth the policies of HELIUS MEDICAL TECHNOLOGIES, INC., a Delaware corporation (the “Company”) prohibiting insider trading; Section III explains insider trading |
|
| March 25, 2025 |
Exhibit 10.9 COMMERCIAL LEASE AGREEMENT ¾ SUMMARY OF BASIC TERMS THIS LEASE AGREEMENT, made this 29th day of November, 2021, by and between Helius Medical Technologies, Inc. (hereinafter referred to as Tenant) and 660 Tudor Square, L.P. (hereinafter referred to as Landlord). WITNESSETH: The Landlord, for and in consideration of the prompt payment of the rent as specified in this Agreement as well |
|
| March 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
Exhibit 10.9.1 660 Tudor Square, L.P. Lease Addendum #1 LANDLORD:660 Tudor Square, L.P. TENANT:Helius Medical Technologies, Inc. PREMISES:642 Newtown Yardley Rd, Suite 215 CURRENT LEASE TERM:January 1, 2022 - March 31, 2025 1. This lease shall be extended for one (1) additional year, ending March 31, 2026. 2. The Minimum Base Rent Schedule shall be as follows: 04/01/2025 - 03/31/2026$3,750.00/mont |
|
| March 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| March 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| January 31, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement Form S-3 (Form Type) Helius Medical Technologies, Inc. |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. |
|
| January 24, 2025 |
Exhibit 10.1 January 21, 2025 To Holder of Common Stock Purchase Warrants of Helius Medical Technologies, Inc. Re:Reload Offer of Common Stock Purchase Warrants To Whom It May Concern: Helius Medical Technologies, Inc. (the “Company”) is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company in consideration for the exercise of (i) the Series A Common |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| January 24, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 24, 2025 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for ba |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| December 23, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| December 23, 2024 |
Exhibit 99.1 Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System Initial order placed with Company’s distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract NEWTOWN, Pa., Dec. 23, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Heli |
|
| November 18, 2024 |
Exhibit 99.2 Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device Management to host business update call today at 9:00am ET NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel the |
|
| November 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| November 18, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has initiated a process, in consultation wit |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HE |
|
| November 8, 2024 |
SC 13G/A 1 hsdt13ga.htm HSDT 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Helius Medical Technologies, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 42328V801 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2024 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| August 12, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results - Company to host call at 4:30pm today - NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results |
|
| August 9, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| July 24, 2024 |
Exhibit 4.8 Helius Medical Technologies, Inc. 2021 Inducement Plan Adopted by the Board of Directors: July 1, 2021 Amended by the Board of Directors: July 2, 2024 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c |
|
| July 24, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| July 24, 2024 |
As filed with the Securities and Exchange Commission on July 24, 2024 Registration No. |
|
| June 28, 2024 |
Exhibit 10.1 AMENDMENT 1 TO HELIUS MEDICAL TECHNOLOGIES, INC. 2022 Equity Incentive Plan RECITALS A.Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (the “Plan”). B.The Plan is amended by this Amendment 1 (this “First Amendment”) in the following respects, effective from and after the date this First |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| May 31, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| May 30, 2024 |
Exhibit 1.01 Helius Medical Technologies, Inc. Conflict Minerals Report For Calendar Year 2023 Helius Medical Technologies, Inc. (“Helius,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2023 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Co |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38445 (Commission file number) 642 Newtown Yardley Road, Suite 100 Newtown, PA (Address of principal executive offices) 18940 (Zip Code) Dane |
|
| May 14, 2024 |
EX-99.1 2 ea020604201ex99-1helius.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing ag |
|
| May 14, 2024 |
SC 13G 1 ea0206042-13gintrahelius.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Helius Medical Technologies, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 42328V801 (CUSIP Number) May 9, 2024 (Date of Event Which Requires Filing of this |
|
| May 13, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results - Company to host call at 4:30pm today - NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results fo |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2024 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| May 9, 2024 |
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering Exhibit 99.1 Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering NEWTOWN, Pa., May 6, 2024 – Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of a public offering of 804,999 shares of its Class |
|
| May 9, 2024 |
Exhibit 4.1 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: May 9, 2024 Issue Date: May 9, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| May 9, 2024 |
Exhibit 4.3 PLACEMENT AGENT WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Issuance Date: May 9, 2024 THIS PLACEMENT AGENT WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, , or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after (Ma |
|
| May 9, 2024 |
Exhibit 4.2 FORM OF SERIES B COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: May 9, 2024 Issue Date: May 9, 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Helius Medical Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 9, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT May 6, 2024 VIA ELECTRONIC DELIVERY Mr. Dane C. Andreeff President and Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Dear Mr. Andreeff: This letter (the “Agreement”) constitutes the agreement between Craig-Hallum Capital Group LLC (“Craig-Hallum” or the “Placement Agent”) and Helius |
|
| May 9, 2024 |
Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: May 9, 2024 Issue Date: May 9, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| May 8, 2024 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-278698 PROSPECTUS HELIUS MEDICAL TECHNOLOGIES, INC. 704,999 Shares of Common Stock Series A Warrants to Purchase up to 2,852,221 Shares of Common Stock Series B Warrants to Purchase up to 2,852,221 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,147,222 Shares of Common Stock This is a best efforts public offe |
|
| May 6, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®) - The Centers for Medicare & Medicaid Services (CMS) released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece - - Public Meeting Scheduled for May 29, 2024 - NEWTOWN, Pa., May 6, 2024– Helius Medical T |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Co |
|
| May 3, 2024 |
May 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Benjamin Richie Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-278698 Acceleration Request Requested Date: May 6, 2024 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant |
|
| May 2, 2024 |
May 2, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1, as amended File No. 333-278698 Withdrawal of Acceleration Request Ladies and Gentlemen: Reference is made to our letter filed as correspondence with the U.S. Securities and Exchange Commissio |
|
| May 1, 2024 |
May 1, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Benjamin Richie Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-278698 Acceleration Request Requested Date: May 2, 2024 Requested Time: 4:05 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Secu |
|
| April 26, 2024 |
Exhibit 4.2 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| April 26, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 26, 2024 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on April 26, 2024 Registration No. 333-278698 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdic |
|
| April 26, 2024 |
Exhibit 4.3 FORM OF SERIES B COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| April 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| April 26, 2024 |
Form of Placement Agency Agreement Exhibit 10.24 PLACEMENT AGENCY AGREEMENT May , 2024 VIA ELECTRONIC DELIVERY Mr. Dane C. Andreeff President and Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Dear Mr. Andreeff: This letter (the “Agreement”) constitutes the agreement between Craig-Hallum Capital Group LLC (“Craig-Hallum” or the “Placement Agent”) and Helius |
|
| April 26, 2024 |
Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| April 26, 2024 |
Form of Placement Agent Warrant Exhibit 4.5 PLACEMENT AGENT WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Issuance Date: May , 2024 THIS PLACEMENT AGENT WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, Craig-Hallum Capital Group, LLC, or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| April 15, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 15, 2024 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on April 15, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| April 15, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 HELIUS ME |
|
| March 28, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results - Company to host call at 4:30pm today – NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today ann |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 28, 2024 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) ( |
|
| March 28, 2024 |
Subsidiaries of Helius Medical Technologies, Inc. Exhibit 21.1 SUBSIDIARIES OF HELIUS MEDICAL TECHNOLOGIES, INC ENTITY NAME JURISDICTION Helius Medical, Inc. Delaware Helius Medical Technologies (Canada), Inc. Canada Helius NeuroRehab, Inc. Delaware Helius Canada Acquisition Ltd. Canada Heuro Canada, Inc. Canada |
|
| March 28, 2024 |
Exhibit 97.1 Helius Medical Technologies, Inc. Policy for the Recovery of Erroneously Awarded Compensation Adopted and approved on November 21, 2023 and Effective as of November 21, 2023 1.Purpose. The Board of Directors (the “Board”) of Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt t |
|
| March 15, 2024 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF helius medical technologies, Inc. (A DELAWARE CORPORATION) March 12, 2024 Table of Contents Page ARTICLE I Offices 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II Corporate Seal 1 Section 3. Corporate Seal 1 ARTICLE III Stockholders’ Meetings 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting. 1 Section 6. Special Mee |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| March 4, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller - Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) - - Proceeds from recent stock issuances through the Company’s At-The-Market (“ATM”) program extends cash r |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| February 6, 2024 |
SC 13G/A 1 ea192883-13ga2intrahelius.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Helius Medical Technologies, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 42328V801 (CUSIP Number) December 31, 2023 (Date of Event |
|
| February 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Helius Medical Technologies, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 42328V801 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| December 4, 2023 |
Exhibit 99.1 Empowering Neuroplasticity PoNS TherapyTM for Balance and Gait Deficits in Patients with Neurological Disorders December 2023 NASDAQ:HSDT Legal Disclaimers This presentation contains forward-looking statements, including statements regarding the Company’s future strategic and operational execution, the success of the Company’s PoNS device and related treatment, the next phase of the C |
|
| December 4, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| November 9, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results - Cash runway extended into Q2 2024 - - Company to host call at 4:30pm today – NEWTOWN, Pa., Nov. 9, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gai |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HE |
|
| November 2, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024 - Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 - - Expects to report approximately $7.0 mill |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| September 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 28, 2023 Date of Report (Date of earliest event reported) Helius Medical Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| September 28, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece - UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology - - PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossing pharmacy benefit managers (PBMs) –- - PoNS expected to be one of few products with both pharmacy |
|
| September 11, 2023 |
HSDT / Helius Medical Technologies Inc - Class A / ANDREEFF DANE - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 05, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporati |
|
| September 5, 2023 |
Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria Exhibit 99.1 Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria NEWTOWN, Pa., September 5, 2023 – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on August 31, 2023, Helius received formal notice |
|
| August 16, 2023 |
Helius Medical Technologies Announces Reverse Stock Split Exhibit 99.1 Helius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa., August 16, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.00 |
|
| August 16, 2023 |
Exhibit 3.1 CORRECTED CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. Helius Medical Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The Certificate of Amendment to the Certificate of Incorporation that was filed with the Delaware Secretary of State |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 16, 2023 Date of Report (Date of earliest event reported) Helius Medical Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation or |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2023 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| August 10, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results - Total Q2 revenue up 115% over prior year; 131% over Q1 2023 - - Company to host call at 4:30pm today - NEWTOWN, Pa., August 10, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulatio |
|
| June 23, 2023 |
Exhibit 1.1 HELIUS MEDICAL TECHNOLOGIES, INC. Class A Common Stock ($0.001 par value per share) Sales Agreement June 23, 2023 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Helius Medical Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Co |
|
| June 23, 2023 |
$1,950,000 Helius Medical Technologies, Inc. Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270433 Prospectus Supplement (to Prospectus dated May 25, 2023) $1,950,000 Helius Medical Technologies, Inc. Class A Common Stock We have entered into a sales agreement, or Sales Agreement, with Roth Capital Partners, LLC, or the Agent, relating to the sale of shares of our Class A common stock, $0.001 par value per share (t |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Helius Medical Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 642 Newtown Yardley Road, Suite 100 Newtown, PA (Address of pr |
|
| May 30, 2023 |
Exhibit 1.01 Helius Medical Technologies, Inc. Conflict Minerals Report For Calendar Year 2022 Helius Medical Technologies, Inc. (“Helius,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2022 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Co |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| May 25, 2023 |
May 25, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Jessica Ansart Re: Helius Medical Technologies, Inc. Registration Statement on Form S-3 File No. 333-270433 Acceleration Request Requested Date: May 26, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Sec |
|
| May 25, 2023 |
As filed with the Securities and Exchange Commission on May 25, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 25, 2023 Registration No. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| May 11, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results - Company to host call at 4:30pm today - NEWTOWN, Pa., May 11, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results fo |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2023 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Co |
|
| April 21, 2023 |
2023 Annual Meeting of Stockholders filed with the SEC on April 21, 2023; TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 7, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| March 24, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that its |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Helius Medical Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 36-4787690 (State or other jurisdiction of incorporation or organization) (IRS Employer Identific |
|
| March 24, 2023 |
Exhibit 3.1 HELIUS MEDICAL TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), that the following resolution was duly adopted by the board of directors of the Corporation (t |
|
| March 10, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.2 HELIUS MEDICAL TECHNOLOGIES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF HELIUS MEDICAL TECHNOLOGIES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking |
|
| March 10, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.4 HELIUS MEDICAL TECHNOLOGIES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF HELIUS MEDICAL TECHNOLOGIES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Helius Meidcal Technologies, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking |
|
| March 10, 2023 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 10, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.1 HELIUS MEDICAL TECHNOLOGIES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF HELIUS MEDICAL TECHNOLOGIES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT(this “Agreement”), dated as of [●], between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking associati |
|
| March 10, 2023 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) Helius Medical Technologies, Inc. |
|
| March 10, 2023 |
Exhibit 4.3 HELIUS MEDICAL TECHNOLOGIES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| March 9, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results - Full year 2022 revenue of $0.8 million, an increase of 51% over 2021 - - Year-end cash balance of $14.5 million - - Company to host call at 4:30pm today - NEWTOWN, Pa., March 9, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech |
|
| March 9, 2023 |
Subsidiaries of Helius Medical Technologies, Inc. Exhibit 21.1 SUBSIDIARIES OF HELIUS MEDICAL TECHNOLOGIES, INC ENTITY NAME JURISDICTION Helius Medical, Inc. Delaware Helius Medical Technologies (Canada), Inc. Canada Helius NeuroRehab, Inc. Delaware Helius Canada Acquisition Ltd. Canada Heuro Canada, Inc. Canada |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 HELIUS ME |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2023 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (C |
|
| February 8, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Helius Medical Technologies, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 42328V603 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Helius Medical Technologies, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 42328V603 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 23, 2023 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| January 23, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022 - Q4 2022 revenue projected to range from $275,000 to $285,000 - - Full year 2022 revenue projected to range from $780,000 to $790,000 - - Unaudited year end cash balance of $14.5 million - NEWTOWN, Pa., January 23, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq |
|
| January 23, 2023 |
Exhibit 99.2 Empowering Neuroplasticity PoNS Therapy ™ for Balance and Gait Deficits in Patients with Neurological Disorders January 2023 NASDAQ:HSDT Legal Disclaimers This presentation contains forward - looking statements, including statements regarding the Company’s future strategic and operati onal execution, the next phase of the Company’s market development activities, clinical and regulator |
|
| January 19, 2023 |
S-8 1 tm233288d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4787690 (State or other jurisdictio |
|
| January 19, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HE |
|
| November 14, 2022 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results - Total Q3 revenue up 80% over prior year - - Cash on hand expected to fund operations through 2023 - - Company to host call at 8:30am today – NEWTOWN, Pa., November 14, 2022 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurol |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation |
|
| September 30, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 26, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) ? - ? ? DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of In |
|
| September 30, 2022 |
Exhibit 16.1 ? September 30, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 26, 2022, to be filed by our former client, Helius Medical Technologies, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. |
|
| September 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 19, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) ? - ? ? Delaware 001-38445 36-4787690 (State or Other Jurisdiction of In |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 15, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) ? - ? ? DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incor |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2022 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results - Net proceeds from August 2022 financing and cash on hand expected to fund operations through 2023 ? - Company to host call at 4:30pm today - NEWTOWN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (?Helius? or the ?Company?), a neurotech company focused on neurologi |
|
| August 15, 2022 |
HSDT / Helius Medical Technologies Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Helius Medical Technologies, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 42328V603 (CUSIP Number) August 5, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| August 15, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| August 9, 2022 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT August 5, 2022 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this ?Agreement?), Helius Medical Technologies, Inc., a Delaware corporation (the ?Company?), hereby agrees to sell up to an aggregate of $18,000,000 of registered securities of th |
|
| August 9, 2022 |
EXHIBIT 4.2 Helius Medical Technologies, Inc. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC as Warrant Agent Warrant Agency Agreement Dated as of August 9, 2022 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of August 9, 2022 (?Agreement?), between Helius Medical Technologies, Inc., a Delaware corporation (the ?Company?), and American Stock Transfer & Trust Company, LLC, a New York |
|
| August 9, 2022 |
EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT helius medical technologies, inc. Warrant Shares: Initial Exercise Date: August 9, 2022 CUSIP: 42328V 702 ISIN: US42328V7029 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| August 9, 2022 |
Form of Pre-Funded Warrant to purchase shares of common stock. EXHIBIT 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT helius medical technologies, inc. Warrant Shares: Initial Exercise Date: August 9, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| August 9, 2022 |
Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering EXHIBIT 99.1 Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering NEWTOWN, Pa., August 5, 2022 ? Helius Medical Technologies, Inc. (Nasdaq: HSDT) (?Helius? or the ?Company?), a neurotech company focused on neurological wellness, today announced the pricing of a public offering of (i) 24,000,000 shares of its Class A common stock (or common stock equivalents in lieu th |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 Helius Medical Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (C |
|
| August 9, 2022 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 5, 2022, between Helius Medical Technologies, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and |
|
| August 8, 2022 |
TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(4)? ?Registration No. 333-266107 and 333-266554? PROSPECTUS HELIUS MEDICAL TECHNOLOGIES, INC. 24,000,000 Shares of Common Stock Warrants to Purchase up to 36,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 24,000,000 Shares of Common Stock This is a best efforts public offering of 24,000,000 shares of our Class A common stock, p |
|
| August 4, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| August 4, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 S-1MEF 1 tm2220595-9s1mef.htm S-1MEF As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 3845 36-4787690 (State or other jur |
|
| August 4, 2022 |
TABLE OF CONTENTS As filed with Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| August 4, 2022 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT helius medical technologies, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?In |
|
| August 4, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| July 29, 2022 |
July 29, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Christine Westbrook Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-266107 Acceleration Request Requested Date: August 2, 2022 Requested Time: 5:00 P.M. Easte |
|
| July 27, 2022 |
Form of Placement Agency Agreement Exhibit 10.21 PLACEMENT AGENCY AGREEMENT , 2022 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this ?Agreement?), Helius Medical Technologies, Inc., a Delaware corporation (the ?Company?), hereby agrees to sell up to an aggregate of $ of registered securities of the Company, includ |
|
| July 27, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| July 27, 2022 |
Form of Securities Purchase Agreement Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between Helius Medical Technologies, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditi |
|
| July 27, 2022 |
As filed with Securities and Exchange Commission on July 26, 2022 TABLE OF CONTENTS As filed with Securities and Exchange Commission on July 26, 2022 Registration No. |
|
| July 27, 2022 |
Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT helius medical technologies, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| July 27, 2022 |
Exhibit 4.2 Helius Medical Technologies, Inc. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC as Warrant Agent Warrant Agency Agreement Dated as of , 2022 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2022 (?Agreement?), between Helius Medical Technologies, Inc.,, a Delaware corporation (the ?Company?), and American Stock Transfer & Trust Company, LLC, a New York limited liabil |
|
| July 27, 2022 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT helius medical technologies, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?In |
|
| July 13, 2022 |
Power of Attorney (incorporated by reference to Exhibit 24.1 to the Form S-1 filed on July 12, 2022) TABLE OF CONTENTS As filed with Securities and Exchange Commission on July 12, 2022 Registration No. |
|
| July 13, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| May 31, 2022 |
Helius Medical Technologies, Inc. Conflict Minerals Report For Calendar Year 2021 EX-1.01 2 brhc10038168ex1-01.htm EXHIBIT 1.01 Exhibit 1.01 Helius Medical Technologies, Inc. Conflict Minerals Report For Calendar Year 2021 Helius Medical Technologies, Inc. (“Helius,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2021 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on May 31, 2022 Registration No. |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Helius Medical Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 642 Newtown Yardley Road, Suite 100 Newtown, PA 18940 (Address |
|
| May 31, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| May 27, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 12, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 12, 2022 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS? - Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing - NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (?Helius? or the ?Company?), a neurotech company focused on neurological w |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q FN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNO |
|
| April 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (C |
|
| April 27, 2022 |
Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS® Exhibit 99.1 Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS? - First patients have purchased PoNS devices to initiate PoNS Therapy - - Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch - NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (?Helius? or the ?Company?), a neurotech |
|
| April 22, 2022 |
DEF 14A 1 ny20002715x2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 8, 2022 |
PRE 14A 1 ny20002715x1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 1, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Com |
|
| April 1, 2022 |
Empowering Neuroplasticity PoNS Therapy for Balance and Gait Deficits in Patients with Neurological Disorders April 2022 NASDAQ:HSDT Exhibit 99. |
|
| March 14, 2022 |
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results Ex 99.1 Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (?Helius? or the ?Company?), a neurotech company focused on neurological wellness, today reported financial results for the quarter and full year ended December 31, 2021. Fourth Quarter and Recent Busin |
|
| March 14, 2022 |
Exhibit 21.1 SUBSIDIARIES OF HELIUS MEDICAL TECHNOLOGIES, INC ENTITY NAME JURISDICTION Helius Medical, Inc. Delaware Helius Medical Technologies (Canada), Inc. Canada Helius NeuroRehab, Inc. Delaware Helius Canada Acquisition Ltd. Canada Heuro Canada, Inc. Canada |
|
| March 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 18, 2022 |
Exhibit 10.3 Standard Stock Option Grant Package HELIUS MEDICAL TECHNOLOGIES, INC. STOCK OPTION GRANT NOTICE (2022 EQUITY INCENTIVE PLAN) Helius Medical Technologies, Inc., a Delaware corporation (the ?Company?), pursuant to its 2022 Equity Incentive Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). |
|
| February 18, 2022 |
Exhibit 10.1 HELIUS MEDICAL TECHNOLOGIES, INC. 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 16, 2022 APPROVED BY THE STOCKHOLDERS: May [?], 2022 1.GENERAL. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returnin |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| February 14, 2022 |
HSDT / Helius Medical Technologies Inc / COLUMBUS CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Helius Medical Technologies, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 42328V504 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 11, 2022 |
HSDT / Helius Medical Technologies Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 HELIUS MEDICAL TECHNOLOGIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42328V603 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 26, 2022 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) ( |
|
| January 26, 2022 |
Exhibit 99.1 Helius Medical Technologies, Inc. Provides Corporate Update - Fourth Quarter 2021 Revenue Projected to Range from $250,000 to $260,000 - - Unaudited Year End Cash Balance of $11 million - - Continued Progress Toward U.S. Commercial Launch of PoNS? for Multiple Sclerosis - - Initiation of Pivotal and Investigator Initiated Trials for Use of PoNS in Stroke Patients Targeted for First Ha |
|
| November 29, 2021 |
Empowering Neuroplasticity PoNS Therapy? for Balance and Gait Deficits in Patients with Neurological Disorders November 23, 2021 NASDAQ:HSDT Exhibit 99. |
|
| November 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 29, 2021 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| November 16, 2021 |
HSDT / Helius Medical Technologies Inc / ANDREEFF DANE - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2021 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| November 12, 2021 |
Exhibit 1.1 1,204,375 SHARES of Common Stock HELIUS MEDICAL TECHNOLOGIES, INC. UNDERWRITING AGREEMENT November 10, 2021 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto 640 Fifth Avenue, 4th Floor New York, New York 10019 Ladies and Gentlemen: The undersigned, Helius Medical Technologies, Inc., a company incorporated under the laws |
|
| November 12, 2021 |
Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock Exhibit 99.1 Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock NEWTOWN, Pa., November 9, 2021 ? Helius Medical Technologies, Inc. (Nasdaq: HSDT) (?Helius? or the ?Company?), a neurotech company focused on neurological wellness, today announced that it has commenced a proposed underwritten registered public offering of shares of its common stock. All |
|
| November 12, 2021 |
Exhibit 99.2 Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering of Common Stock NEWTOWN, Pa., November 10, 2021 ? Helius Medical Technologies, Inc. (Nasdaq: HSDT) (?Helius? or the ?Company?), a neurotech company focused on neurological wellness, today announced the pricing of an underwritten registered public offering of 1,204,375 shares of its common |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2021 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| November 10, 2021 |
Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results Ex 99.1 Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results NEWTOWN, Pa., November 10, 2021 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (?Helius? or the ?Company?), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2021. Third Quarter and Recent Business Updates ? Received U.S |
|
| November 10, 2021 |
1,204,375 shares of Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-236101 PROSPECTUS SUPPLEMENT (to the Prospectus dated February 6, 2020) 1,204,375 shares of Class A Common Stock We are offering 1,204,375 shares of our Class A common stock, par value $0.001 per share (the ?common stock?). Our common stock is listed on The Nasdaq Capital Market under the symbol ?HSDT?. On November 8, 2021, th |
